ARTICLE | Clinical News
Erbitux cetuximab: Additional Phase II data
May 26, 2008 7:00 AM UTC
ImClone reported additional data from the previously reported European Phase II OPUS trial of Erbitux in 337 patients. The new data showed an overall response rate of 61% for Erbitux plus FOLFOX chemo...